



“Providing an opportunity for multiple myeloma patients and their loved ones to come together to exchange information for mutual support, comfort, and friendship”

**Meeting: Tuesday April 21, 2015 3:30pm – 5:30pm**  
**451 Junction Road**  
**UW West Clinic Room 1287**  
**Enter the clinic... proceed left past the vending area... turn left again and conf. room 1287 is the last one on the left.**

**Information:** Jayne Schwartz 608- 244-2120  
[schwartzdon@sbcglobal.net](mailto:schwartzdon@sbcglobal.net)

**Mailing Address:** Wisconsin Multiple Myeloma Support Group  
3309 Chicago Avenue  
Madison, WI 53714-1815

**More Information:**

International Myeloma Foundation (IMF)	Multiple Myeloma Research Foundation (MMRF)
Phone: 800 - 452 - 2873	203 - 972 - 1250
Email: <a href="mailto:TheIMF@myeloma.org">TheIMF@myeloma.org</a>	<a href="mailto:info@themmrf.org">info@themmrf.org</a>
Website: <a href="http://www.myeloma.org">www.myeloma.org</a>	<a href="http://www.multiplemyeloma.org">www.multiplemyeloma.org</a>

**Upcoming speakers**

Debbie Boldt-Houle, Senior Director Scientific Affairs from the Binding Site, Inc needed to reschedule her presentation. She will join us in July. She will present information about the Freelite testing. Tentative plans for Dr Natalie Callander to speak at the October meeting

**The Multiple Myeloma Research Foundation Commends the U.S. Food and Drug Administration (FDA) Approval of Novartis' Farydak (Panobinostat) for Multiple Myeloma** Norwalk, Conn., February 24, 2015 –

The Multiple Myeloma Research Foundation (MMRF) praises the Food and Drug Administration's (FDA) decision to approve Farydak (panobinostat) for patients with advanced myeloma and treatment resistant multiple myeloma. Farydak is approved in combination with Velcade (bortezomib) and dexamethasone for the treatment of multiple myeloma for patients who have received at least two prior standard therapies, including bortezomib and an immunomodulatory (IMiD) agent.

*“The MMRF commends the diligence of Drs. Pazdur, Farrell and the Division of Hematology Products at FDA, as well as the myeloma community, working with Novartis in approving the first histone deacetylase (HDAC) inhibitor, an entirely new and important class of treatments for multiple myeloma,” said Walter M. Capone, President and Chief Executive Officer of the Multiple Myeloma Research Foundation. “In particular, their enlightened efforts to specify the profile of patients most likely to benefit from Farydak will enable patients and their doctors to access a vital new option for the most challenging relapsed disease.”*

*“The promise of the HDAC class of drugs, that targets malignant cells in a completely different manner, is an important advance in helping patients whose myeloma is progressing despite prior treatments and can contribute to our mission of attaining cures for all patients,” added Capone.*

I am attaching an interesting article about “Sadness” and how to move through it. Hope you find it helpful.  
**7 Steps to Move Through Sadness (and What We Can Learn from It) By [Barbara Scoville](#)**

## **BMT InfoNet Free Webinar – Tuesday, April 21 at 6:30pm CT**

If you have multiple myeloma, chances are you are either considering or have had a stem cell transplant. Get the facts about how to prepare for and survive a stem cell transplant at our free live webinar: [Stem Cell Transplants for Multiple Myeloma: What you need to know before, during and after transplant.](#)

All you need is a phone and a computer to join myeloma and transplant expert, Dr. David Vesole, for an in-depth discussion about:

- the different types of multiple myeloma.
- when a patient should consider an autologous stem cell transplant.
- what is involved in undergoing an autologous stem cell transplant.
- options for consolidation therapy after transplant.
- the prognosis for those who choose an autologous stem cell transplant versus other available therapies.
- when an allogeneic transplant using donor cells may be an appropriate treatment option.

Presenter: David Vesole, MD. Dr. Vesole is a well-known figure in the myeloma community. He is Co-Director of the Myeloma Division and Director of Myeloma Research at the John Theurer Cancer Center at Hackensack University Medical Center. He is also Professor of Medicine, Rutgers University Medical School and Georgetown University.

Dr. Vesole is a Foundation for the Accreditation of Cellular Therapy (FACT) inspector and serves on the Clinical Standards, Accreditation and Data Management Committees for FACT. He is a member of the International Myeloma Foundation Scientific Advisory Board and serves on the Board of Trustees for the Leukemia and Lymphoma Society, New York City Chapter.

Dr. Vesole has authored more than 180 articles in peer-reviewed medical journals and has presented his research at medical meetings and symposia nationally and internationally. He earned his MD from Northwestern University and a PhD in immunology and microbiology from the Medical University of South Carolina. Register online at [www.bmtinfonet.org](http://www.bmtinfonet.org).

## **Get Help with Co-Pays**

Do you or someone you love need help paying co-payments for chemotherapy and cancer medications? The **CancerCare® Co-Payment Assistance Foundation (CCAF)** is dedicated to helping people afford their co-payments for chemotherapy and targeted treatment medications.

We currently have funds available for these diagnoses:

- Metastatic breast cancer
- Non-small cell lung cancer (NSCLC)
- Colorectal cancer
- Pancreatic cancer
- Glioblastoma
- Gastric cancer
- Multiple myeloma

[Visit our website](#) or call **866-55-COPAY** (866-552-6729) to learn more or to enroll.

**IMF Info Line** – If you or someone you care for has myeloma, you have questions. Probably, lots of them. You can search the Internet all you want, but other than asking your doctor, there is no better way to get your questions answered than to call the IMF Info Line. Debbie, Missy, Judy and Paul know their stuff and they want to share what they know with you. Just ask anyone who has called the IMF Info Line. Patients or caregivers are welcome to contact the Info Line staffed by trained specialists at 800-452-CURE (800-452-2873). The Info Line is staffed between 9am and 4pm Pacific Time, 11am to 6pm Central time or [info@myeloma.org](mailto:info@myeloma.org).

**The Trillium Fund** was established by our founding support group members to facilitate Multiple Myeloma research here in Madison at the Wisconsin Institute of Medical Research. If you or your family wish to donate or send a memorial to this program, checks can be made payable to the “UW Foundation – Trillium Fund”.

Send to: Maureen Dembski, Director of Development

UW Carbone Cancer Center

University of Wisconsin Foundation

1848 University Avenue

Madison, WI 53726

[maureen.dembski@supportuw.org](mailto:maureen.dembski@supportuw.org)